Title
Artificial intelligence approaches to predicting and detecting cognitive decline in older adults: A conceptual review.

Permalink
https://escholarship.org/uc/item/21q1z3qm

Authors
Graham, Sarah A
Lee, Ellen E
Jeste, Dilip V
et al.

Publication Date
2020-02-01

DOI
10.1016/j.psychres.2019.112732

Peer reviewed
Artificial intelligence approaches to predicting and detecting cognitive decline in older adults: A conceptual review

Sarah A. Graham, Ellen E. Lee, Dilip V. Jeste, Ryan Van Patten, Elizabeth W. Twamley, Camille Nebeker, Yasunori Yamada, Ho-Cheol Kim, Colin A. Depp

Department of Psychiatry, University of California San Diego, La Jolla, CA, United States
Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, CA, United States
IBM-UCSD Artificial Intelligence for Healthy Living Program, La Jolla, CA, United States
VA San Diego Healthcare System, San Diego, CA, United States
Department of Neurosciences, University of California San Diego, La Jolla, CA, United States
Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, United States
Accessibility and Aging, IBM Research-Tokyo, Tokyo, Japan
Scalable Knowledge Intelligence, IBM Research-Almaden, San Jose, CA, United States

ARTICLE INFO

Keywords:
Dementia
Mild cognitive impairment
Machine learning
Sensors
Natural language processing

ABSTRACT

Preserving cognition and mental capacity is critical to aging with autonomy. Early detection of pathological cognitive decline facilitates the greatest impact of restorative or preventative treatments. Artificial Intelligence (AI) in healthcare is the use of computational algorithms that mimic human cognitive functions to analyze complex medical data. AI technologies like machine learning (ML) support the integration of biological, psychological, and social factors when approaching diagnosis, prognosis, and treatment of disease. This paper serves to acquaint clinicians and other stakeholders with the use, benefits, and limitations of AI for predicting, diagnosing, and classifying mild and major neurocognitive impairments, by providing a conceptual overview of this topic with emphasis on the features explored and AI techniques employed. We present studies that fell into six categories of features used for these purposes: (1) sociodemographics; (2) clinical and psychometric assessments; (3) neuroimaging and neurophysiology; (4) electronic health records and claims; (5) novel assessments (e.g., sensors for digital data); and (6) genomics/other omics. For each category we provide examples of AI approaches, including supervised and unsupervised ML, deep learning, and natural language processing. AI technology, still nascent in healthcare, has great potential to transform the way we diagnose and treat patients with neurocognitive disorders.

1. Introduction

The World Health Organization (WHO) defines healthy aging as the process of developing and maintaining the functional ability that enables well-being in older age (World Health Organization, 2019). Cognitive health is one of the most important determinants of functional ability of older adults (Beaton et al., 2015; Dodge et al., 2005; Gross et al., 2011), is critical to aging with autonomy (Depp and Jeste, 2006; Willis et al., 2006). Healthy aging is associated with some cognitive decline in select abilities (e.g., processing speed, fluid reasoning, episodic memory (Der et al., 2010; Eckert, 2011)), a proportion of older adults develop mild cognitive impairment (MCI; labeled mild neurocognitive disorder in the DSM-5 (American Psychiatric Association, 2013)), and 5%–15% progress to dementia (major neurocognitive disorder) annually (American Psychiatric Association, 2013; Mitchell and Shiri-Feshki, 2009, 2008; Petersen, 2011). Worldwide, 50 million people have dementia (World Health Organization, 2019). As there is no known cure for dementia, tools for the earliest possible detection of cognitive decline are necessary to achieve the greatest impact of current and novel treatment approaches to delay pathological cognitive aging (Graham and Depp, 2019).

Unfortunately, early detection of cognitive impairment is a challenging psychometric endeavor due to the insidious progression of symptoms, which, in the early stages, may be mistaken for normal age-related cognitive impairment (Deary et al., 2009; Petersen et al., 2001). MCI can be difficult to clearly identify, due to multiple sets of
diagnostic criteria and need for longitudinal follow-up (Brodaty et al., 2017). Furthermore, MCI may precede varying types of dementia and does not lead to dementia in a sizable proportion of patients. Knowing which patients warrant a comprehensive cognitive screening can be challenging for clinicians, and neuropsychological test batteries are time-consuming and require trained administration. An ideal diagnostic tool must be sensitive to the earliest signs of cognitive decline, non-invasive, practical, and scalable for use in clinics worldwide. Similar efforts are already underway (Balota et al., 2016; Patten et al., 2018; Silverberg et al., 2011) with incremental progress, but there remains much room for improvement.

The purpose of this conceptual review is to provide a primer for clinicians on the understanding and use of an exciting new approach to supporting clinical decision-making such as diagnosis, prediction, and differentiation between the various types of MCI and dementias – i.e., artificial intelligence (AI). AI refers to the scientific field within the discipline of computer sciences concerned with building systems or machines (computers) to accomplish tasks that typically require human intelligence, such as making decisions. Machine learning (ML), deep learning (DL), and natural language processing (NLP) are techniques of AI. For a machine to act intelligently, it needs to learn from data (trained with data). In ML, algorithms are used to enable the machine to learn through structured data input and past experience to detect patterns in the data and use uncovered patterns to predict future human data. ML can be supervised (i.e., tested against dependent variable data that are known or labeled) or unsupervised (i.e., with data that are unknown or unlabeled). DL is a subset of ML that is useful when there is a large amount of complex and unstructured data. DL involves multiple layers of algorithms called artificial neural networks (ANN), each providing a hierarchically different interpretation to the data. NLP is family of techniques that focuses on analysis of natural human language (usually written) and can be integrated with any of the ML approaches. AI applications specifically for drug discovery, causal disease modeling, clinical trials recruitment, and neuropsychiatric symptoms are outside the scope of this review and have been previously examined in the literature (Jiang et al., 2017; Zhavoronkov et al., 2019).

2. Artificial intelligence primer for predicting and detecting cognitive decline

AI in healthcare is the use of computational algorithms and software that mimic human cognitive functions to analyze complex structured and unstructured medical data like images or clinical notes (Jiang et al., 2017; Yu et al., 2018). AI tools use these high-dimensional (i.e., multi-feature) data to determine potential predictors of normal versus pathological changes in cognitive functioning. AI analytic techniques are ideally suited to handle large volumes and complexity of datasets and can do this more efficiently than humans (Raghupathi and Raghupathi, 2014; Wang et al., 2016). Machine learning (ML) is a subset of AI that involves various methods of enabling an algorithm to learn from datasets, or update itself based on new data (Chen et al., 2017; Nevin, 2018). Standard statistics emphasize fitting a specific model and hypothesis testing to understand underlying mechanisms. In contrast, ML algorithms do not require a priori hypotheses about relationships among variables, and instead, emphasize prediction accuracy and can often detect unforeseen relationships and complicated nonlinear interactions within data (Graham et al., 2019). The results or “performance” of an AI algorithm depend on the model selected, available data, and the input features the researchers selected to predict an outcome. Below we narrate the most common classes of ML used for healthcare purposes: supervised and unsupervised machine learning (SL and UL) (Bzdok et al., 2018; Fabris et al., 2017; Miotto et al., 2016), and deep learning (DL) (Esteve et al., 2019; Miotto et al., 2017) (Fig. 1a), which may or may not involve natural language processing (NLP) (Demner-Fushman et al., 2009; Hirschberg and Manning, 2015) (Fig. 1b).

Supervised Learning (SL) approaches require pre-labeled data (e.g., diagnosis of cognitive impairment vs. unimpaired) that serve as known outcomes for training an algorithm along with features derived from additional data streams (e.g., clinical notes, neuroimaging) (Bzdok et al., 2018; Fabris et al., 2017). The algorithm then determines which features are most predictive of the pre-labeled outcome. The diagnosis of cognitive impairment could be based on either categorical classification (yes or no) or continuous regression (e.g., score on a neurocognitive assessment) (Fig. 1a). The validity of SL algorithms rely heavily on the “ground truth” behind the labeled outcomes, which may require longitudinal follow-up or other information to bolster the determination of outcomes such as cognitive impairment.

Unsupervised Learning (UL) algorithms are provided with unlabeled data. While the data may contain, for example, individuals with cognitive impairment and those without, the algorithm is not privy to this information (Miotto et al., 2017). Instead, the algorithm searches unstructured data (e.g., clinical notes) for relationships or clusters with the goal of segmenting the data by some shared characteristics, or detecting anomalies that do not belong to a particular group. Identified clusters generally require clinical expertise to derive their meaning (Fig. 1a).

Deep Learning (DL) functions using both SL and UL but is capable of exploiting the unknown structure from data using artificial neural networks (ANNs) that automatically derive features from raw data (i.e., feature engineering) when they learn, instead of requiring human input for obtaining features from raw data (Esteve et al., 2019; Miotto et al., 2017). This type of learning requires very large datasets in comparison to other forms of ML that can work with smaller data size and extensive computation power. Complex, high-dimensional data like neuroimaging and speech are well suited to DL (Fig. 1a).

Natural Language Processing (NLP) refers to how computers understand natural language (e.g., speech, text) in terms of language translation, semantic understanding, and summarization (Demner-Fushman et al., 2009; Hirschberg and Manning, 2015). The process of NLP is to transfer text from an unstructured into a structured format to enable analyzes. Studies that use NLP generally follow with one of the aforementioned learning techniques (SL, UL, DL) to determine the accuracy of using speech/text data to model cognitive function (Fig. 1b).

2.1. Performance metrics of AI results

AI studies most commonly report results of algorithm performance as percent accuracy and receiver operating characteristic area under the curve (ROC AUC). Accuracy is the proportion of correct predictions: true positives + true negatives divided by all observations (true positives and negatives + false positives and negatives) (Hossin and Sulaiman, 2015; Huang and Ling, 2005). In comparison, AUC provides information about the trade-off between sensitivity (true positive rate) and specificity (true negative rate) at various threshold settings. The benefit of using AUC instead of, or in addition to, percent accuracy, is that unlike accuracy this metric is not affected by class imbalance (e.g., a smaller number of subjects in the sample with dementia compared to healthy controls) (Hossin and Sulaiman, 2015).

When evaluating the efficacy or quality of the results of AI studies, we should pay close attention to the validation methods used to arrive at the performance metrics. A study has been internally validated if methods like cross validation (CV) were used. CV is considered “internal” validation because all of the data are used at some point in the training phase (e.g., leave one out CV; 5-fold CV) (Blagus and Lusa, 2015). The performance is reported as the average across the testing folds. CV enables the researcher to double-check the accuracy of a model on different subsets of data, though the algorithm has not been vetted on a population external to the one used for training. In contrast, external validation involves testing the algorithm performance on a completely different dataset than the training set (Park and Han, 2018). This step is crucial before an algorithm’s clinical usefulness can be
3. Overview of select studies focused on AI for cognitive decline

We did not perform a meta-analysis of all studies related to neurocognitive disorders and AI. Instead, our goal was to provide a guide to aid clinicians in understanding the heterogeneity and potential value and limitations of a variety of neurocognitive features for AI applications. Using a broad MEDLINE inquiry with several search terms [(“artificial intelligence” or “machine learning” or “NLP”) AND (“cognition” or “cognitive testing”),] we then selected studies to illustrate the diversity of data sources and research questions addressed using AI, preferring those with larger sample sizes and clear explanations of the ML approach.

We selected studies that showcased common classes of features used for detecting, classifying, or predicting cognitive status and that employed the most common AI techniques emerging in healthcare: SL, UL, DL, and NLP (Jiang et al., 2017). Six feature categories (i.e., types of datasets) emerged from the studies selected: sociodemographic data, clinical and psychometric assessments; neuroimaging and neurophysiological data; electronic health record (EHR) and claims data; novel assessments (e.g., handwriting and speech analyzes); and genomic and other omic data. Table 1 showcases different AI techniques used with each feature category, with its strengths and limitations.

3.1. Sociodemographic data (Table 1 section A)

Sociodemographic and other forms of population data offer rich information from large datasets (e.g., the US Health and Retirement Study (Institute for Social Research, University of Michigan, 2019. Health and Retirement Study); Aging and Retirement in Europe (SHARE-ERIC, 2019); Korean Longitudinal Study of Aging (Korean Employment Information Services. 2015. Korean Longitudinal Study of Aging. https://survey.keis.or.kr/eng/klosa/klosa01.jsp)). De Langavant et al. (2018) developed an UL-based algorithm for identifying participants with high likelihood of dementia from population-based surveys,
### Table 1
Summary of characteristics of selected studies of AI for cognitive impairment.

<table>
<thead>
<tr>
<th>Authors/Journal/Location</th>
<th>Primary Aim</th>
<th>Subjects/Dataset</th>
<th>Predictors (features) used by AI algorithm</th>
<th>Validation</th>
<th>Best algorithm and performance/Main finding(s)</th>
<th>Strengths and limitations of using these features with AI analytic approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sociodemographic data (section A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Langavant et al., 2018</td>
<td>Identify participants with high likelihood of dementia in population-based surveys without clinical diagnosis</td>
<td>N = 18,165 training (59% F) n = 56,202 test (57% F)</td>
<td>Survey-based data including demographics, health, health care utilization, &amp; cognition</td>
<td>UL</td>
<td>Algorithm: Hierarchical clustering; identified 3 clusters based on functional &amp; motor (walking, climbing) limitations. Performance: Cluster 3 (high risk for dementia) accuracy = 93.1%; AUC = 0.91. Main findings: Ul identified high likelihood of dementia in population-based surveys, even without cognitive &amp; behavioral measures &amp; without clinical diagnosis of dementia.</td>
<td>Strengths: - More generalizable to other samples due to being commonly collected data. - Larger sample sizes due to public registries. - Inclusive of all demographic groups. - Contains social determinants of health. - Beneficial for resource poor areas with limited primary care access &amp; limited cognitive testing capacities. Limitations: - Lack clinical/biological information that may allow for more precise diagnoses.</td>
</tr>
<tr>
<td>Na, 2019</td>
<td>Predict cognitive impairment using variables commonly collected in community health care institutions</td>
<td>N = 3,424 community-dwelling older adults Age 70.4 ± 7.0 years, without cognitive impairment based on MMSE (53.7% F)</td>
<td>Socio-demographic, health, functional, &amp; subjective well being</td>
<td>SL</td>
<td>Main findings: Cognitive decline best predicted by: age, MMSE, &amp; education.</td>
<td></td>
</tr>
<tr>
<td>Clinical and psychometric assessments (section B)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lim et al., 2017</td>
<td>Predict MCI &amp; dementia from demo-graphic &amp; standard neuro-cognitive test features</td>
<td>N = 151 (25% held out as test set); n = 70 adults with clinical diagnosis of MCI 71.3 ± 7.5 yrs; n = 56 adults with dementia 76.9 ± 7.5 yrs; 25 HCs 69.1 ± 5.1 yrs Database from Molecular Markers in Degenerative Diseases</td>
<td>Gender, age, level of education, study time, &amp; scores from cognitive tests (MMSE, Semantic Verbal Fluency Test, CDR, &amp; Ascertaining Dementia).</td>
<td>SL</td>
<td>Algorithm:RF: only cognitive tests. Performance: Accuracy = 96.8%, sensitivity = 0.98, specificity = 0.96. Main findings: Using only cognitive testing (MMSE, CDR, AD8) was best for predicting cognitive status.</td>
<td>Strengths: - Direct assessment of cognitive functioning. - Standard scoring metrics and comparison to validated norms. - High relevance to clinicians. Limitations: - Certain assessments require clinical suspicion and more resources to obtain (e.g., neuropsychological testing). - Cognitive data are derived from contrived testing situations.</td>
</tr>
<tr>
<td>Moreira and Namen 2018</td>
<td>Determine whether unstructured mining of medical texts improves diagnosis of MCI &amp; AD</td>
<td>N = 605; characterized in model as ≥65 or &lt;65 years (gender not specified but also included in model) patients attending the Alzheimer &amp; Parkinson Center in the city of Campos dos Goytacazes</td>
<td>Demographic, clinical, neuro-psych screening tests, and clinical notes</td>
<td>NLP / UL / SL</td>
<td>Algorithm: Best model for AD: J48 with AdaBoost ensemble method including UL x-means clustering. Performance: accuracy = 0.80 &amp; AUC = 0.85. Main findings: Greater effectiveness of a hybrid (UL/SL) model for diagnosing AD and MCI. Cholinesterase notes contain important information that should not be ignored.</td>
<td></td>
</tr>
</tbody>
</table>

(continued on next page)
Clinical and psychometric assessments (section B)

Senanayake et al., 2017
ICPRAM
UNSW, Sydney, Australia

Distinguish between CN & MCI using neuro-psychological test scores

\[ N = 1037 \] (70–90 years (57% F)) Community-dwelling non-demented adults (MMSE score ≥24)
MCI (CDR=0.5 criteria) further divided into atMCI & naMCI
Data from the Sydney Memory & Aging Study (MAS)

Between 28 and 35 neuro-psychological test scores (depending on enrollment wave)

DL X

Algorithm: SAE
CN vs. MCI
Performance:
Accuracy = 83%; AUC = 88% MCI subtypes
Accuracy = 76%; AUC = 80%

Main findings: Neuropsychological measures can differentiate between MCI and its subtypes. DL SAE has significant advantages over conventional classifiers; SAE can be used as an unsupervised feature extractor; model will further improve with higher dimensional data.

Neuroimaging and neurophysiologic data (section C)

Fan et al., 2018
Frontiers in Neuroscience
North-eastern University, Boston, MA

Discover the altered spatio-temporal patterns of EEG complexity associated with AD pathology in different severity levels

\[ N = 123 \] adults from the Dementia Clinic at the Neurological Institute, Taipei Veterans General Hospital in Taiwan (AD diagnosed with NINCDS-ADRDA Criteria)
HC \[ N = 15 \] (CDR=0.5)
N = 15; AD2 (CDR=1) \[ N = 69 \]; & AD3 (CDR=2) \[ N = 24 \]

Multiscale Entropy of EEG, a complexity measure of time series signals

SL X

Algorithm: LASSO:
HC vs. AD3
Performance: accuracy = 79.5%
AD1 vs. AD3 accuracy = 82%
AD2 vs. AD3 accuracy = 72.4%

Main findings: Temporal & occipitoparietal brain regions were more discriminative for classifying severe AD vs. NC, but more diverse & distributed patterns of EEG complexity in the brain were exhibited across individuals in early stages of AD

Strengths:
- Systematic approach to complex, multi-layered imaging data. (In other fields, AI techniques can detect imaging abnormalities on par with trained physicians)
- Potential to improve interpretability and clinical utility of certain commonly-obtained but incompletely-understood imaging data
- Hypothesis-generating potential for brain-based mechanisms
- Can guide development of targeted therapies using neurostimulation approaches.

Limitations:
- Expensive (thus, smaller sample sizes, less generalizability)
- Heterogeneity of datasets (imaging Modalities, machines, processing approaches) that make it challenging to harmonize data
- Less tightly correlated with real-world functional outcomes than clinical and neuropsychological data

Gamberger et al., 2017
Scientific Reports
Duke University Medical Center

Identify different prognostic cognitive trajectories of MCI patients through discovering homogenous clusters based on neuro-imaging, clinical Data, & cognitive tests

\[ N = 562; 74.0 \pm 7.5 \text{ years} \]
Data from ADNI database: ADNI-1 & ADNI-2 late MCI subjects with at least one post-baseline visit (criteria available in ADNI procedures manual [http://www.adni-info.org/]) (39% F)

Clinical, cognitive, & biomarker (volumetric brain MRI, amyloid PET, FDG-PET, spinal fluid) tests

UL X

Algorithm: Multi-layer clustering; two clusters identified—rapid vs. slow decliners.

Performance:
Best predictor: baseline ADAS13 > 19.50 yielded 92% sensitivity & 93.7% specificity in ADNI1 & 98.4% sensitivity & 90% specificity in ADNI2

Main findings: Pathological differences between rapid vs. slow decliners included an almost 5-fold greater rate of converting to dementia in rapid vs. slow cluster, & a lower rate of reverting back to cognitively normal (0% vs. 13%)

(continued on next page)
### Neuroimaging and neurophysiologic data (section C)

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
<th>Sample Size</th>
<th>Outcome</th>
<th>Data Collection</th>
<th>Analysis</th>
<th>Performance</th>
<th>Main Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grassi et al., 2018</td>
<td>Prediction of 3-year conversion to AD in subjects with MCI &amp; Pre-MCI from clinical &amp; MRI data</td>
<td>Mount Sinai Medical Center, Miami Beach, Florida, &amp; the Community &amp; Memory Disorders Center at the University of South Florida</td>
<td>n = 75 older adults with DSM-criteria diagnosis of AD; age NR n = 197 HC; age NR n = 61 older adults meeting CDR criteria for MCI (out of sample) 70 + years (60% F)</td>
<td>Clinical &amp; neuro-psychological testing, cardiovascular risk, rating of MRI data</td>
<td>SVM</td>
<td>AUC = 0.996 for AD vs. HC</td>
<td>SVM: AUC = 0.821 MCI</td>
<td>Clinically available data can be used to predict 3-year conversion from MCI to AD</td>
<td></td>
</tr>
<tr>
<td>Iizuka et al., 2019</td>
<td>Diagnose DLB &amp; AD from brain SPECT scans</td>
<td>Fukujuji Hospital, Japan</td>
<td>n = 240 (80 each for DBL 77.9 ± 5.3 years, AD 77.8 ± 5.42 years, &amp; NL 77.7 ± 5.0 years) training; n = 60 (20 each) for training DLB, AD, &amp; NL (McKeith criteria &amp; NINCDS-ADRDA) (52% F)</td>
<td>SPECT images with emphasis on CIS</td>
<td>CNN</td>
<td>accuracy for differentiating DLB-NL=93%; DBL-AD=89%; AD-NL=92% AUCs for differentiating DLB–NL ==0.95; DLB–AD ==0.94; AD-NL ==0.94</td>
<td>DL was useful for differentiating DLB from AD, &amp; for predicting clinical features of DLB. CIS was more involved in discrimination of DLB–AD rather than DLB–NL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### EHR and claims data (section D)

<table>
<thead>
<tr>
<th>Study</th>
<th>Title</th>
<th>Authors</th>
<th>Institution</th>
<th>Sample Size</th>
<th>Outcome</th>
<th>Data Collection</th>
<th>Analysis</th>
<th>Performance</th>
<th>Main Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nori et al., 2019</td>
<td>Predict ADRD 4–5 years in advance from administrative claims data</td>
<td>Optum Labs, Cambridge, MA,</td>
<td>N = 44,945 with ADRD N = 2,901,044 NC Age 77.2 ± 7.0 yrs training data; (62% F training) (27% training; 73% test) ADRD diagnosis (medical claim codes) Data from 2001–2015 from the Optum Labs Data Warehouse (OLDW); all 50 states represented</td>
<td>over 10,000 clinical, pharmaceutical, and demographic variables</td>
<td>LASSO &amp; regularized logistic regression</td>
<td>AUC 0.69 test data</td>
<td>Patients identified by the model 6.4 times more likely to be diagnosed with dementia in the near-term</td>
<td>Potential to detect at-risk patients seeking healthcare for reasons other than cognitive decline</td>
<td>Large and longitudinal datasets</td>
</tr>
</tbody>
</table>

**Strengths:**
- Potential to detect at-risk patients seeking healthcare for reasons other than cognitive decline
- Large and longitudinal datasets

**Limitations:**
- Quality and quantity of EHR data for individuals are dependent on external factors (severity of illness, insurance rules, psychosocial resources, regional practices and resources). For example, sicker patients will likely have more contact with the healthcare system and more documentation within the EHR.
- EHR data may not reflect assessments or work-up that were recommended by providers but declined by the patient.
- EHR data is heterogeneous in organization and level of detail on the provider, clinic, and system-levels, e.g., a geriatric specialty clinic may order a different panel of tests and assessments compared to a primary care clinic.

| Shao et al., 2019 | Identify cases of undiagnosed dementia from both structured & unstructured EHR data | VA Puget Sound | n = 1,861 Veterans with (79.8 yrs) & n = 9,905 without (79.5 yrs) ICD-9 dementia codes (3.3% F) Data from the clinical data warehouse (CDW) within the Veterans Affairs Informatics & Computing Infrastructure (VINCI) | Structured data (diagnosis [ICD codes], procedures [CPT codes], medications, & clinical document types); unstructured data (clinical document text) | LDA | 853 features identified (290 topics, 174 non-dementia ICD codes, 159 CPT codes, 59 medications, & 171 note types) | imperfect data (e.g., ICD codes in combination with other EHR features) can be used to detect Veterans with undiagnosed dementia |

**Main Findings:**
- Imperfect data can be used to detect Veterans with undiagnosed dementia

**Strengths:**
- Potential to detect at-risk patients seeking healthcare for reasons other than cognitive decline

(continued on next page)
Table 1 (continued)

**EHR and claims data (section D)**

<table>
<thead>
<tr>
<th>Wang et al., 2019 JAMA network open</th>
<th>Predict mortality from demographic &amp; clinical notes, highlight topics that best predict mortality to detect patients that may benefit from palliative services</th>
<th>Patients with dementia Training: n = 24,229 [60% F, 74.8 ± 13.2 years] Test: n = 2,692 [61% F, 75.0 ± 12.6 years] Data from Partners HealthCare System patients who visited from 1/1/11 through 12/31/17</th>
<th>959,628 clinical notes, demographics, death status</th>
<th>DL / NLP</th>
<th>X X</th>
<th>Algorithm: LSTM 6-month mortality Performance: AUC 0.978 test data 1-year mortality AUC 0.956 test data 2-year mortality AUC 0.943 test data Main findings: Top-ranked latent topics associated with 6-month, 1- &amp; 2-year mortality included palliative &amp; end-of-life care, cognitive function, delirium, testing of cholesterol levels, cancer, pain, use of health care services, arthritis, nutritional status, skin care, family meeting, shock, respiratory failure, &amp; swallowing function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang et al., 2018 AMIA Annual Symposium Proceedings Harvard Medical School, Boston, MA</td>
<td>Evaluated topic models for important themes mentioned in care provider notes about dementia patients; explored patterns &amp; trends of topics over the final 2 years of life</td>
<td>n = 7,875; Age 84.3 ± 9.5 years at death with dementia (54.5% F) (432,007 clinical notes) n = 133,394 HC Age 71.9 ± 16.5 years at death Patients with dementia from two PHS hospitals: Brigham &amp; Women’s Hospital &amp; Faulkner Hospital</td>
<td>All types of inpatient &amp; ambulatory notes—office visit notes, progress notes, discharge summaries, emergency department notes, consultations, nutrition notes, social work notes, phone calls</td>
<td>UL / NLP</td>
<td>Main findings:</td>
<td>Novel assessments (speech, handwriting, sensors) (section E)</td>
</tr>
<tr>
<td>Akl et al., 2015 IEEE Trans Biomed Eng University of Toronto, Canada</td>
<td>Detect MCI using home-based sensing technology</td>
<td>N = 97 older adults 80+ years from Portland, Oregon, metropolitan area living alone either CN or MCI (CDR criteria) (90% F)</td>
<td>Motion detected with passive infra-red motion sensors &amp; walking speed</td>
<td>SL</td>
<td>X</td>
<td>Algorithm: SVM Performance: AUC = 0.97 Main findings: Trajectories of weekly walking speed, GoV of walking speed, GoV of morning &amp; evening walking speeds, age, gender were most important for detecting MCI in older adults</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>Table 1 (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Novel assessments (speech, handwriting, sensors) (section E)</strong></td>
</tr>
<tr>
<td><strong>Handwriting information: x &amp; y coordinates of pen position; pen inclination; pen pressure; pen airtime</strong></td>
</tr>
<tr>
<td><strong>Algorithm:</strong> Ensemble classifier</td>
</tr>
<tr>
<td><strong>Performance:</strong> accuracy = 84%; AUC = 87%</td>
</tr>
<tr>
<td><strong>Main findings:</strong> Detect dementia automatically from results</td>
</tr>
<tr>
<td><strong>Angelillo et al., 2019</strong></td>
</tr>
<tr>
<td><strong>IEEE Access</strong></td>
</tr>
<tr>
<td><strong>University of Bari, Italy</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Digitalization of the AMT enables capturing a larger set of performance measures than can be obtained from the paper-based test; the best performance measures of a cognitive impairment task were prolonged in-air time.</td>
</tr>
<tr>
<td><strong>Predict cognitive status by monitoring hand-washing behaviors at a long-term care facility.</strong></td>
</tr>
<tr>
<td><strong>N = 27 participants; 82.4 ± 9.5 years; (81.4% F) with MMSE scores ranging from 28 to 30.</strong></td>
</tr>
<tr>
<td><strong>Ashraf and Taati 2016</strong></td>
</tr>
<tr>
<td><strong>IEEE Journal of Informatics</strong></td>
</tr>
<tr>
<td><strong>University of Toronto, Canada</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Most significant differences between groups in speech tempo from delayed recall task, number of pauses for question-answering task, and number of pauses for question-answering task.</td>
</tr>
<tr>
<td><strong>Toth et al., 2018</strong></td>
</tr>
<tr>
<td><strong>In Proceedings APSIPA Annual Summit &amp; Conference</strong></td>
</tr>
<tr>
<td><strong>University of California Los Angeles</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Classifier accuracy using the optimal feature subset was higher than when only using a neuro-psychological test.</td>
</tr>
<tr>
<td><strong>Gwak et al., 2018</strong></td>
</tr>
<tr>
<td><strong>Current Alzheimer Research</strong></td>
</tr>
<tr>
<td><strong>Memory ambulance of the University of Szeged, Hungary</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Identified 13 novel candidate genes that could have a potential role in AD pathology.</td>
</tr>
<tr>
<td><strong>Haran et al., 2019</strong></td>
</tr>
<tr>
<td><strong>mBio</strong></td>
</tr>
<tr>
<td><strong>Jawaharlal Nehru University, New Delhi, India</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Microbiome of AD shows a lower proportion &amp; prevalence of bacteria with the potential to synthesize butyrate, &amp; higher abundances of taxa known to cause pro-inflammatory states.</td>
</tr>
<tr>
<td><strong>Jamal et al., 2016</strong></td>
</tr>
<tr>
<td><strong>BMCGenomics</strong></td>
</tr>
<tr>
<td><strong>New Delhi, India</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Limitations of large datasets. Discover new roles of genes in the pathogenesis of cognitive decline. Identify numerous microbial taxa &amp; functional genes that act as drug targets.</td>
</tr>
<tr>
<td><strong>Lack of access to biological samples-Not routinely collected Longitudinal stool samples of key buyar producing species in AD, JAD, healthy controls, &amp; other clinical states.</strong></td>
</tr>
<tr>
<td><strong>Husain et al., 2019</strong></td>
</tr>
<tr>
<td><strong>University of Massachusetts Medical School, Worcester, Massachusetts</strong></td>
</tr>
<tr>
<td><strong>Main findings:</strong> Longitudinal stool samples of neurologically normal and AD, PPI and PPI which may cause AD, and PPI which may act as targets. **</td>
</tr>
</tbody>
</table>
Table 1 continued

| ZHOU et al., 2018 | Predict AD & its prodromal status from multimodal imaging & genetic features | MRI, PET (93 ROIs) & SNP | DL X Algorithm: | Performance: DNN MRI+PET+SNP highest accuracy = 65% |

**Main findings:** The combination of brain imaging & genetic features produced the highest accuracy in classifying AD vs. MCI vs. HC

**AD=Alzheimer's Disease; ADNI= Alzheimer’s Disease Neuroimaging Initiative; AI=artificial intelligence; AMT= attentional matrices test; AUC=area under the curve; CDR=clinical dementia rating; CN=control; CNN=convolutional neural network; CoV=coefficient of variation; CV=cross validation; DL=deep learning; DNN=deep neural network; F=female; GBM=gradient boosting model; HC=healthy control; KLoSA=KoreanLongitudinalStudyofAging; LDA=latent Dirichlet allocation; LSTM=long short-term memory; MCI=mild cognitive impairment; MMSE=minimental state examination; NB=naïve bayes; NLP=natural language processing; PPG=photoplethysmography; RF=random forest; ROI=region of interest; SAE=stacked auto-encoder; SHARE= ... SL=supervised learning; SVM=support vector machine; UL=unsupervised learning.**

---

3.2. Clinical and psychometric assessments (Table 1 section B)

Clinical assessment data offer readily available, inexpensive, and rich sources of information. The three studies highlighted in this category show how AI techniques can be used to streamline a cognitive assessment battery for dementia (Lins et al., 2017), incorporate information from clinical notes to improve diagnostic accuracy of MCI (Moreira and Namen, 2018), and best distinguish between normal cognition and MCI using neuropsychological measures (Senanayake et al., 2017). The three studies differ widely in sample size, input data, and algorithms, demonstrating the varied applications of such data. Given that every major healthcare provider collects clinical variables, these data promote generalizability of ML algorithms and can potentially involve large samples if every individual in an area or healthcare system is included. Similar to population-based sociodemographics, clinical data may be best for identifying high-risk individuals who need additional assessments and clinical interventions to help focus resources most efficiently. However, clinical assessments are not streamlined or standardized (primary versus subspecialty settings), and different clinicians may use different measures (e.g., the Montreal Cognitive Assessment (MoCA) versus the MMSE). AI may be able to address the limitations of heterogeneous data by using a heterogeneous training set, or by testing models in different populations. ML techniques may also help to rank the factors that are critical for assessing cognitive impairment and thus help to focus on these factors. The quality and accuracy of clinical data can be variable and require detailed record-keeping and access to the data to be useful for AI.

3.3. Neuroimaging and neurophysiological data (Table 1 section C)

Neuroimaging and neurophysiological techniques have grown considerably in the past decade. Research continues to demonstrate their use for providing important information about the brain's structure and function (Khandai and Aizenstein, 2013). Brain imaging is often used to detect neurological causes (e.g., tumors, stroke), but not psychopathology (Vernooij et al., 2019). In the interpretation of radiological without clinical diagnosis, using both American and European subjects, with the potential to flag individuals within a large population-based sample for cognitive screening. The Na study (Na, 2019) used variables commonly collected in community health care institutions (sociodemographics, health, subjective well-being) and foundage and education were particularly important in predicting cognitive decline in a community sample of Korean adults.

A benefit of such data is that they are often stratified geographically and cover various demographic groups. They are also easy to collect for reasonable cost and can be widely disseminated. Such data can potentially help with early risk stratification and subsequent identification of high-risk individuals in need of more detailed assessments (De Langavant et al., 2018). These data may also contain social determinants of health (e.g., education), often overlooked in other clinical data. Because many countries collect population data regarding health, socioeconomic status, and social and family networks of older adults, such information may also provide an opportunity to compare outcomes across different countries and infer global health estimates of dementia burden. However, simply identifying putative risk and protective factors for cognitive decline from sociodemographic data may be of limited use for predicting future cognitive impairment for an individual. Furthermore, the findings from one country/setting may not relate directly to participants in other nations, e.g., extrapolating from a Korean sample to a US sample or vice versa. However, when combined with clinical measures like the Mini-Mental State Examination (MMSE), as shown by Na (2019), sociodemographics could be a useful addition to a ML algorithm. Multi-modal variables are most meaningful when their complex interactions are analyzed comprehensively, and longitudinally (e.g., Na, 2019), using ML models.
images, AI techniques can outperform specialists in detecting early or “preclinical” degradation of neuroanatomy because AI is particularly well suited to detecting abnormalities within image and signal data through training (i.e., pattern recognition) (Ahmed et al., 2019; Hosny et al., 2018). AI offers the potential to improve interpretability and clinical utility of neuroimaging and neurophysiological data that are commonly obtained but incompletely understood. We may learn from AI about new aspects of brain function and connectivity and generate new hypotheses regarding brain-based mechanisms of neuropsychiatric diseases. The four examples of AI used with brain imaging data show how different EEG (Fan et al., 2018) and brain imaging profiles (Gamberger et al., 2017; Grassi et al., 2018; lizuka et al., 2019) can be used to identify cognitive impairment (Fan et al., 2018; lizuka et al., 2019) and predict prognostic trajectories (Gamberger et al., 2017; Grassi et al., 2018) in different populations.

Neuroimaging and neurophysiological data are considered high dimensional data—data where the number of features often greatly exceeds the number of observations. Because most statistical analyzes are better suited for lower dimensional data, ML is an ideal alternative for traditional neuroimaging/neurophysiology analyzes. Given recent initiatives to grow open source datasets like the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (e.g., (Gamberger et al., 2017)), the “big data” required for optimal AI techniques are also available. Ultimately, combining AI techniques with rich biological information contained in neuroimaging will enable faster, safer, cheaper, and more accurate imaging results, usable for informing diagnoses, prognoses, and treatment decisions. However, neuroimaging and neurophysiological assessments are not commonly offered in all medical settings because of high costs and safety issues like radiation exposure. There is also considerable heterogeneity among datasets regarding imaging modalities (magnetic resonance imaging or MRI versus positron emission tomography or PET), machines (different strengths of MRI machines), and processing approaches which continue to evolve.

3.4. Electronic health record (EHR) and claims data (Table 1 section D)

The EHR includes huge amounts of patient-specific information containing both structured (coded) and unstructured (free text) entries (Hayrinen et al., 2008). EHR may also contain some sociodemographic and clinical data mentioned above, depending on the vendor and/or health organization. The four highlighted studies in this section used nationwide administrative claims data (Nori et al., 2019), EHR from a regional Veterans Affairs (VA) healthcare system (a publicly administered program) (Shao et al., 2019), EHR from a regional not-for-profit academic healthcare system (Wang et al., 2019), and EHR from two hospital-based samples (Wang et al., 2018). These datasets record and help to manage patient care and offer a relatively inexpensive source of information collected over long time periods on large numbers of patients. The large size of these databases (i.e., thousands of individuals) enables studies of rare conditions, and the longitudinal aspect of the data enables researchers to investigate effects of treatment(s) over time.

Nori et al., 2019 and Wang et al., 2019 utilized the longitudinal nature of EHR data to find features related to increased incidence of near-term (4-5 years) dementia (Nori et al., 2019) and mortality (Wang et al., 2019). ML algorithms can deal with very large numbers of potential input features (e.g., Nori et al., 2019) used over 10,000 clinical, pharmaceutical, and demographic variables and rapidly develop predictive models without specific selection of variables, enabling automated selection of high value predictors. However, EHR data alone have relatively limited predictive power when analyzed in the absence of other social determinants of health (e.g., population-based sociodemographic data) (Freij et al., 2019).

EHR systems are primarily designed for streamlining billing purposes; thus, the data for deciphering and supporting clinical decision-making may not always be available. The quality and quantity of EHR data are also dependent on external factors (e.g., severity of illness, insurance rules, regional practices, availability of resources) and are heterogeneous in organization and level of detail. For example, the findings from a regional VA health system (as in Shao et al., 2019) may be more representative of care at other VA health systems, whereas there may be considerable regional differences within other nationwide insurers (e.g., Blue Cross Blue Shield versus Kaiser Permanente) due to different patient populations and plan structures. AI will be particularly useful with these data if it can “learn” the different styles of documentation from different providers and different healthcare systems - a excellent area for NLP applications. Finally, AI could help healthcare providers to better and more efficiently understand their patient’s clinical history and guide their decision-making process.

Claims data, like those used by Nori et al., 2019, are generated primarily for the administration of payment for health services delivered. These data offer structured information on patient interactions with a healthcare system (e.g., billed services, prescriptions) and has the ability to link records with other large registries (e.g., death records, cancer databases). Unlike EHRs, claims only offer limited information on clinical severity and patients’ health status, without laboratory, imaging, and other diagnostic test results. Furthermore, claims records do not reflect treatments and assessments that were suggested by clinicians and refused by patients. Claims data have the advantage, however, of collecting data from various sites that may not be included in a single EHR and result in a nationally representative sample. They may help to identify and reduce common biases in healthcare, e.g., when combined with other clinical data, they can help determine which conditions were undiagnosed in some patients, and at what point in time, so that future ML algorithms can detect early markers and indicators of future disease. Potential disadvantages to claims data include differences in values between billed and paid claims, confidentiality issues, and negative consequences like premiums based on personal traits potentially affecting insurability.

3.5. Novel assessments (sensors, handwriting, speech) (Table 1 section E)

Novel features like sensor (digital) data, handwriting (text), and speech (audio), offer unique opportunities to identify new indicators of cognitive decline (Kourtis et al., 2019). The five exemplar studies in Table 1 include home-based motion sensors (Akl et al., 2015), computerized handwriting analyzes (Angelillo et al., 2019), videotaped handwashing tasks (Ashraf and Taati, 2016), multi-modal wearable activity monitors (Gwak et al., 2018), and audio-recorded speech data (Toth et al., 2018) for detecting cognitive impairment. These data (particularly environmental and wearable sensors) have the potential for continuous, longitudinal tracking of cognitive changes. For example, Akl et al. (2015) installed passive infrared motion sensors in participants' homes to assess movements and general activity by location that may be indicative of MCI over a 3-year period. They found that novel features like the trajectories of weekly walking speed were among the most important for detecting MCI in older adults. However, current relationships of these novel data with cognitive status are not yet well characterized. Furthermore, the sensor data contain artifacts (visitors, noise) and have considerable heterogeneity across individuals and environments (one- versus two-faucet handles, microphone position). Nonetheless, sensors offer an opportunity for tracking real-world behaviors in more ecologically valid environments than traditional laboratory or clinic settings. Longitudinal sensor data are particularly difficult to visualize, understand, and manage without specialized algorithms provided by ML.

3.6. Genomic and other omics data (Table 1 section F)

Genomic data are probably the best example of the big data ideally suited to ML analytic techniques. DL, in particular, is most useful when large amounts of data are available, and the human genome comprises more than 3 billion base pairs with a multitude of complex processes...
governing the expression of different genes (Libbrecht and Noble, 2017). Despite major advances in genomics, we still do not fully understand the various genes’ functions and how they impact our physiology and health. Gene expression data can be used to learn to distinguish among different disease phenotypes and identify potentially valuable disease biomarkers. Alzheimer’s Disease (AD), for example, is partially heritable and genetically complex. Large genome databases can offer enough training data to build accurate prediction models relating to gene expression, genomic regulation, or variant interpretation associated with AD and other cognitive impairments. The three studies highlighted in this section include a study of specific genes from a large NIH database (Jamal et al., 2016), gut microbiome analyzes (Haran et al., 2019), and single-nucleotide polymorphism (SNP) data integrated with brain imaging (Zhou et al., 2018). The field of genomics is central to the precision medicine movement, as the illnesses an individual may experience are determined to a variable extent by their genes. ML has also enabled direct-to-consumer applications of genomic analyzes like “23andMe” and “Ancestry.com.” ML approaches have been leveraged to annotate a variety of genomic sequence elements (e.g., splice sites, promotors, enhancers), differentiate among different disease phenotypes, identify disease biomarkers, and investigate mechanisms underlying gene expression. However, genome-wide association studies (GWAS) for polygenic diseases like AD require extremely large sample sizes, which may limit the depth of phenotypic data and thus reduce the accuracy of these algorithms (e.g., 80% for Jamal et al. (2016); 65% for Zhou et al., 2018).

4. Discussion

4.1. High-dimensional data for AI

Different feature types for helping to detect, classify, and predict early pathological cognitive decline in older adults have varied strengths and limitations. The best-performing AI algorithms will require multi-feature data (Jiang et al., 2017) to personalize the findings to the level of the individual patient with their unique bio-psycho-social makeup (Havelka et al., 2009). For example, models based on only EHR data are likely to be biased due to the lack of important information about everyday functioning (e.g., physical function, social connections) that is also critical for health aging (Jeste et al., 2019). Based on this small subsample of studies, a wide variety of features (socio-demographic and clinical factors, specific cognitive tests, functional impairments, mobility problems, speech patterns, electroencephalogram (EEG) measures, MRI-derived brain structures, PET and single-photon emission computerized tomography (SPECT) scan findings, and genes) were found to be associated with or predictive of cognitive impairment. To improve diagnosis and prognosis for adults with cognitive decline, AI research will require large, comprehensive, multi-feature datasets that are collected longitudinally to better predict cognitive trajectories over time (Chi et al., 2017).

Developing such datasets entails several inherent challenges. Ongoing efforts to continually curate large-scale datasets like the ADNI and the UK Biobank databases will be key to the clinical success of AI, though they are costly and labor-intensive. Some claims and EHR companies are currently in search of feasible and legal ways to link these data with health risk assessments, sociodemographic data, and vital signs on a broad basis to create a more holistic picture of patients’ health (Freij et al., 2019). Furthermore, large-scale availability of novel features may be limited by proven clinical utility. For example, while neuroimaging or biosensor data can provide rich, multi-feature input for an AI algorithm, such data would not be available without broad insurance coverage and access to laboratory facilities (Crown, 2015).

4.2. Future directions for AI and neurocognitive research

AI’s strength lies in its ability to accommodate large quantities of multimodal data. Thus, AI can aid better understanding of unique factors and behaviors associated with cognitive decline that have been previously difficult to quantify, e.g., loneliness or social isolation (Biddle et al., 2019; Linggongoro and Torous, n.d.), resilience and wisdom (Meeks and Jeste, 2009), and behavioral symptoms like agitation and psychosocially (Cheng, 2017; Feast et al., 2016). Capturing these factors and behaviors will require leveraging technology and novel inputs like mobile devices and sensor signals that are continually increasing in popularity and place low burden on the healthcare system (Kouris et al., 2019).

The temptation may be to include the “kitchen sink” when developing a ML model because these algorithms enable a much larger set of predictor variables than commonly used in clinical research. However, features should still be evaluated for their validity in terms of potential relationships to the outcome of interest. It is also possible to create increasingly precise algorithms with additional features or continually fine-tuning the ML algorithm – though this may raise the likelihood of overfitting the model such that the algorithm is too customized for the particular training data and would not transfer well to another sample (Park and Han, 2018).

ML methods are subject to the same challenges and sources of bias encountered in observational data analyzes using traditional statistical approaches. While small and labeled datasets for specific tasks are easier to collect, the resultant algorithms may not transfer to other datasets. In contrast, large and unlabeled datasets are also fairly easy to collect, but require a shift toward semi-supervised or unsupervised learning techniques that are harder to train (Esteva et al., 2019). Implementation of standards for AI/ML studies will be key to ensuring study quality. The US Food and Drug Administration (FDA) recently released a white paper (US Food and Drug Administration, 2019) soliciting advice (by June 3rd, 2019) from stakeholders to help developers bring AI devices to market. The considerations discussed therein pertain to transparency, interpretability, and replication as components of “good ML practices”. The World Economic Forum has also recommended a governance structure, safety and efficacy regulations, and responsible practices in the development of technological tools (World Economic Forum). Governmental regulation may be essential to establish regulatory guidelines for AI applications in research like those endorsed by the EQUATOR network (Equator Network. 2019. Enhancing the QUality and Transparency Of health Research). The Computing Community Consortium also recently published a 20-year community roadmap for AI research (Gil and Selman, 2019), citing integrated intelligence (e.g., creating open-shared repositories of machine-understandable world knowledge); meaningful interaction (e.g., techniques for productive collaboration in mixed teams of humans and machines); and self-aware learning (e.g., developing causal and steerable models from numerical data and observations) as research priorities to realize societal benefits.

All of the studies presented in this overview focused on diagnosis or prediction of a neurocognitive disease. Algorithms to detect neurocognitive impairments may be able to support the decision-making capabilities of an experienced clinician, but they will not replace clinical expertise. No studies to date have directly compared clinical diagnostic accuracy of a neurocognitive disorder head-to-head with an AI approach, so the efficacy of these algorithms remains to be determined, with a few exceptions (Brinker et al., 2019; Lindsey et al., 2018; Nam et al., 2019). An accurate prediction of a patient diagnosis also does not provide clinicians with direction to change that outcome. However, AI could potentially expedite patient diagnoses if it can flag patients that are in need of immediate care or follow-up (Savage, 2019). If AI could further supplement clinical knowledge with less common datastreams, it may lend considerable support to individualizing prognoses and treatment decisions. Clinicians will require background knowledge regarding AI to decipher results and gauge the utility of such information (for an excellent guide applied to radiology, see (Park and Han, 2018)). Collaboration between clinicians and AI experts will be
key to continual development of AI models, as clinicians can share their deep understanding of clinical populations – and the heterogeneity among individuals and over time – that will aid AI researchers in refining AI algorithms and transferring them to other populations.

4.3. Ethics of using AI for neurocognitive disorders

The ethical and social implications of using AI for detection and prediction of neurocognitive disorders include the need to weigh benefits against potential risks to patients. The benefits could be better healthcare; however, it is important to consider bias and accountability (Challen et al., 2019). For example, a risk may stem from whether the algorithm was built upon data that are not representative of the patient in question (e.g., older adults from underrepresented minorities), and subsequently presents a diagnosis that is questionable. Moving forward, there will need to be procedures to account for, and take action to mitigate, potential bias to avoid exacerbating inequities. AI models must be deployed in diverse samples to ensure generalizability. Moreover, how a decision is derived by the algorithm needs to be transparent to the clinician (Samek et al., 2017) so that a questionable recommendation can be examined before action is taken.

Within the context of diagnosing and predicting the trajectory of dementia, there are many disease-specific concerns. Once an individual is diagnosed with dementia, there can be serious legal and financial consequences, including the ability to make decisions, live independently, and even drive motor vehicles (Cornett and Hall, 2008). Algorithms can increasingly be applied to smartphones and other products that are widely distributed, based on inputs such as keyboard typing patterns (White et al., 2018). While highly scalable, data ownership and privacy issues are a concern especially since regulations to protect user privacy are lacking, which may expose more people to surreptitious cognitive health surveillance. For example, passive surveillance tools applied to smartphone usage or social media posts could negatively impact ones job security, driving license, and insurance premiums (Rosenfeld and Torous, 2017). With such high stakes, the medical community must follow evidence-based practices to diagnose and treat their patients and pharmacotherapies must undergo rigorous clinical trials prior to approval by the FDA. Similarly, AI-derived algorithms must meet clinical standards. However, the threshold of proof and utility of AI models is not yet established.

Adopting AI algorithms in clinical practice carries the additional challenge of establishing trust in the model. The “black box” of ML presents a unique problem in how we reconcile the AI model’s results with our clinical experience and the scientific literature. The movement to develop Explainable AI (XAI) may aid the ability of clinicians to communicate these findings with other clinicians as well as with patients and their families to guide clinical decision-making (Gunning, 2017). XAI involves efforts to address a machine’s ability to explain its decisions and actions to users. The goal is explainable models that still have a high level of performance. Ultimately, health-care liability remains with the clinician; thus, AI tools need to best explain its decisions and actions to users. The goal is explainable methods to enable meaningful systematic analysis.

5. Conclusion

AI technology holds remarkable promise for transforming the way we diagnose and treat patients with neurocognitive disorders. There exist a large variety of potential features that in combination can comprehensively characterize the bio-psycho-social determinants of a unique individual and thus enable more personalized understanding of cognitive decline. The performance and potential clinical utility of ML algorithms for detecting, diagnosing, and predicting cognitive decline using these features will continue to improve as we leverage multi-feature datasets on large datasets. Establishing guidelines for research involving AI applications in healthcare will be necessary to ensure the quality of results, as will engagement of clinicians (as well as patients and their caregivers) so that they may contribute their expertise in the refinement of AI algorithms. With the assistance of AI, early detection of cognitive decline may not be as difficult as it is today.

Declaration of Competing Interest

Authors YY and HK are employees of IBM. The other authors have no conflicts of interest to report.

Acknowledgments

This study was supported, in part, by the National Institute of Mental Health T32 Geriatric Mental Health Program (grant MH019934 to DVJ [PI]), NIMH K23MH119375-01 (PI: EEL), the IBM Research AI through the AI Horizons Network IBM-UCSD AI for Healthy Living (AHIL) Center, by the Stein Institute for Research on Aging at the University of California San Diego, and by the National Institutes of Health, Grant UL1TR001442 of CTSA funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Supplementary materials


References


World Health Organization, 2019. Dementia [https://www.who.int/news-room/fact-sheets/detail/dementia].


World Health Organization, 2019. Dementia [https://www.who.int/news-room/fact-sheets/detail/dementia].


World Health Organization, 2019. Dementia [https://www.who.int/news-room/fact-sheets/detail/dementia].


World Health Organization, 2019. Dementia [https://www.who.int/news-room/fact-sheets/detail/dementia].

